• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Allurion Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8/13/25 8:15:29 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care
    Get the next $ALUR alert in real time by email
    8-K
    false000196497900019649792025-08-132025-08-130001964979alur:WarrantsToPurchase1420455SharesOfCommonStockEachAtAnExercisePriceOf810PerShareOfCommonStockMember2025-08-132025-08-130001964979alur:CommonStockParValue00001PerShareMember2025-08-132025-08-13

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 13, 2025

     

     

    Allurion Technologies, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-41767

    92-2182207

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    11 Huron Drive

     

    Natick, Massachusetts

     

    01760

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (508) 647-4000

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common stock, par value $0.0001 per share

     

    ALUR

     

    The New York Stock Exchange

    Warrants to purchase 0.056818 shares of common stock, each at an exercise price of $202.50 per share of common stock

     

    ALUR WS

     

    The New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On August 13, 2025, Allurion Technologies, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2025. The full text of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

     

    In connection with preparation of the Company’s unaudited quarterly financial statements for the quarter ended June 30, 2025, a potential miscalculation of Other Comprehensive Income (Loss) and Other Income (Expense), which are non-cash items, was recently identified, related to the fair value of the Revenue Interest Financing Agreement (RIFA) and convertible notes. The Company is evaluating the calculation of such amounts for prior periods and believes that it is likely that such calculations will result in a restatement of its financial statements for such periods. The Company does not expect, however, that the calculation of such amounts will have any impact on revenue, gross margin, operating expenses, or cash.

    The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

    Item 7.01 Regulation FD Disclosure.

    The information set forth in Item 2.02 above is incorporated by reference herein. Such information is intended to be furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

     

     

    Exhibit

    Description

    99.1

    Press Release issued by the registrant on August 13, 2025 furnished herewith.

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    ALLURION TECHNOLOGIES, INC.

     

     

     

     

    Date:

    August 13, 2025

    By:

    /s/ Brendan M. Gibbons

     

     

    Name:

    Title:

    Brendan M. Gibbons
    Chief Legal Officer

     


    Get the next $ALUR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALUR

    DatePrice TargetRatingAnalyst
    11/14/2024Buy → Neutral
    Chardan Capital Markets
    10/2/2024$2.00Buy
    TD Cowen
    9/6/2024$2.00Buy
    ROTH MKM
    2/9/2024$5.00Buy
    Jefferies
    More analyst ratings

    $ALUR
    SEC Filings

    View All

    SEC Form 424B3 filed by Allurion Technologies Inc.

    424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    8/15/25 6:05:47 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    SEC Form NT 10-Q filed by Allurion Technologies Inc.

    NT 10-Q - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    8/15/25 6:05:29 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Allurion Technologies Inc.

    424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    8/15/25 6:04:50 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    5/21/25 4:15:08 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Director Rtw Investments, Lp converted options into 1,492,539 shares (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    4/17/25 6:36:58 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    4/1/25 4:15:07 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    5/21/25 4:15:08 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    4/1/25 4:15:07 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Allurion Technologies downgraded by Chardan Capital Markets

    Chardan Capital Markets downgraded Allurion Technologies from Buy to Neutral

    11/14/24 8:29:33 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Allurion Technologies with a new price target

    TD Cowen initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

    10/2/24 7:13:57 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    ROTH MKM initiated coverage on Allurion Technologies with a new price target

    ROTH MKM initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

    9/6/24 7:25:38 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update

    Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and provided a business update. Recent Company Highlights and Outlook Announced new strategic direction focused on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry Signed term sheet with strategic partner to enhance manufacturing and distribution capabilities and R&D pipeline, including the potential joint development of a novel, GLP-1 drug-eluting balloon Submitted protocol for prospective, multi-center trial on combination therapy with low-dose GLP-1s and the Allurion Program to achieve weight los

    8/13/25 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025

    Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 (646) 960-0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay

    8/7/25 4:05:00 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry

    Signed term sheet with strategic partner to enhance distribution capabilities and R&D pipeline, including the potential joint development of a novel, GLP-1 drug-eluting balloon Submitted protocol to IRBs for approval on prospective, multi-center trial on combination therapy with low-dose GLP-1s and the Allurion Program to achieve weight loss while maintaining muscle mass and increasing GLP-1 adherence Commenced transition to distribution partners with access to physician networks prescribing GLP-1 therapy and equipped to deliver metabolically healthy weight loss PMA application for the Allurion Balloon successfully accepted by FDA for evaluation Preliminary, unaudited second quarter

    8/5/25 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Financials

    Live finance-specific insights

    View All

    Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update

    Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and provided a business update. Recent Company Highlights and Outlook Announced new strategic direction focused on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry Signed term sheet with strategic partner to enhance manufacturing and distribution capabilities and R&D pipeline, including the potential joint development of a novel, GLP-1 drug-eluting balloon Submitted protocol for prospective, multi-center trial on combination therapy with low-dose GLP-1s and the Allurion Program to achieve weight los

    8/13/25 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025

    Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 (646) 960-0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay

    8/7/25 4:05:00 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Reports First Quarter 2025 Financial Results and Provides Business Update

    Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update. Recent Company Highlights and Outlook Maintaining 2025 revenue guidance of approximately $30 million with a reduction of approximately 50% in operating expenses compared to 2024 First quarter revenue of $5.6 million and operating expenses of $11.4 million, a 37% decrease in operating expenses compared to prior year; adjusted operating expenses of $10.1 million, a 45% decrease compared to prior year Net operating loss of $7.3 million, a 36% reduction compared to prior year; adj

    5/14/25 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Leadership Updates

    Live Leadership Updates

    View All

    Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

    Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "I believe having Keith as a sounding board as we leverage the opportunities created by GLP-1s will be a competitive advantage." Omar Ishrak, Al

    9/3/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial

    Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company's international commercial sales and operations functions. "We are thrilled to welcome Adrian to Allurion and add his expertise to our leadership team as we advance the company toward profitability," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "Adrian joins us at an extremely important time – where the obesity market is expandi

    8/20/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

    Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working closely with the Board and Executive Leadership Team. Ojas will provide strategic and execution-focused guidance aimed to help the company achieve major milestones and scale sustainably. With a 25-year track record in the health

    6/5/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

    SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    11/14/24 4:43:43 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

    SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    11/14/24 4:15:52 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Allurion Technologies Inc.

    SC 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    10/24/24 5:19:39 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care